Table 1 Baseline characteristics
Characteristic | ||
|---|---|---|
Age, years | ||
|  | Median (range) | 62 (31–85) |
Sex, n (%) | ||
| Â | Male | 37 (47.4) |
| Â | Female | 41 (52.6) |
ECOG performance status, n (%) | ||
| Â | 0 | 15 (19.2) |
| Â | 1 | 56 (71.8) |
| Â | 2 | 7 (9.0) |
Histology, n (%) | ||
| Â | Adenocarcinoma | 78 (100) |
Stage, n (%) | ||
| Â | IV | 78 (100) |
Brain metastases, n (%) | ||
| Â | No | 58 (74.4) |
| Â | Yes | 20 (25.6) |
Smoking status, n (%) | ||
| Â | Former | 22 (28.2) |
| Â | Never | 51 (65.4) |
| Â | Unknown | 5 (6.4) |
EGFR mutation status, n (%) | ||
| Â | Positive | 6 (7.7) |
| Â | Negative | 72 (92.3) |
ALK fusion status, n (%) | ||
| Â | Positive | 0 |
| Â | Negative | 78 (100) |
Pyrotinib treatment line, n (%) | ||
| Â | 1 | 23 (29.5) |
| Â | 2 | 15 (19.2) |
|  | ≥ 3 | 40 (51.3) |
Previous afatinib therapy | ||
| Â | Yes | 21 (26.9) |
| Â | No | 57 (73.1) |
HER2 mutation, n (%) | ||
| Â | Exon 20 mutation | 62 (79.5) |
| Â | Non-exon 20 mutation | 16 (20.5) |